Thank you for joining us in 2022!

Gynecologic Cancer Immunotherapy

Friday
November 11, 2022, 3:55 pm -
4:30 pm
New potential in gynecologic cancers

Session Description

Globally, ovarian cancer is diagnosed in an estimated 300,000 women each year—and another 570,000 are diagnosed with cervical cancer and 382,000 with uterine (endometrial) cancer. While significant advances have been made in surgical and chemo-based treatments for ovarian cancer, the survival rates have only modestly improved. Immunotherapy for ovarian cancer shows tremendous potential for addressing this devastating disease. In this session, Dr. Kunle Odunsi, director of the University of Chicago Medicine Comprehensive Cancer Center, will discuss details of immunotherapy clinical trials in ovarian cancer currently underway and take your questions about new treatments in gynecologic cancers.

Speaker(s)

Kunle Odunsi, MD, PhD

University of Chicago Medicine Comprehensive Cancer Center

Dr. Kunle Odunsi is the director of the University of Chicago Medicine Comprehensive Cancer Center and dean for oncology at the University of Chicago’s Biological Services Division. He has broad oversight responsibility for all University of Chicago cancer programmatic aspects and sets the organization’s strategic direction which emphasizes research, collaborative cancer discovery and care, outreach and engagement, and development opportunities for early career and promising cancer researchers. His research efforts focus upon the mechanisms of immune recognition in ovarian cancer and the pre-clinical and clinical development of tumor antigen targeted therapies, which are currently being studied in several cancer immunotherapy clinical trials. His contributions to science include the first demonstration of the importance of intraepithelial CD8+ T cell infiltration on favorable outcomes in ovarian cancer patients and the discovery of unique T cell receptors from rare subsets of CD8+ and CD4+ antigen specific T cells. Dr. Odunsi has received many accolades for his work including the Society for Immunotherapy of Cancer Team Science Award in 2020, The Robert, Anne, & Lew Wallace Endowed Chair in Cancer Immunotherapy in 2019, the Ovarian Cancer Research Alliance’s Rosalind Franklin Prize for Excellence in Ovarian Cancer Research in 2019, election to the National Academy of Medicine in 2018, and the Lifetime Achievement in Medicine and Research Award from Medaille College in 2015.